Thrombocytopenic Purpura Clinical Trial
Official title:
An Open-label, Unit Dose-finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03244410 -
Lymphocyte Counts in Immune Thrombocytopenic Purpura
|
N/A | |
Completed |
NCT00454857 -
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
N/A | |
Completed |
NCT01444417 -
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
|
Phase 3 | |
Completed |
NCT00508820 -
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
|
Phase 3 | |
Completed |
NCT00415532 -
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
|
Phase 3 |